CHINA – Evonik China and Shandong Vland Biotech have begun market expansion efforts for their joint venture, Evonik Vland Biotech aimed at bolstering their market presence and fortifying their product offerings. 

The venture, which commenced operations on January 1 and was officially inaugurated in Qingdao on March 14, marks a significant milestone in the collaboration between the two parent companies.

The primary objective behind this partnership is to amplify the market reach of their products, particularly focusing on probiotics for enhancing the gut health of livestock in the Greater China region. 

Additionally, the joint venture aims to spearhead the development of novel products and solutions to cater to evolving market demands.

Johann-Caspar Gammelin, head of Evonik’s Nutrition & Care division, highlighted the robust foundation established through the decade-long partnership between Vland and Evonik. 

Gammelin emphasized the pivotal role of Vland in Evonik’s strategy to furnish the feed industry with biosolutions, particularly probiotics, for animal gut health.

Evonik’s biotech platform is geared towards pioneering biosolutions that promote a healthy life across various domains, spanning chemistry, biotechnology, pharmacology, and data science. 

The joint venture seeks to leverage this expertise to introduce innovative products and solutions, with a particular emphasis on applications in skin health, complementing Evonik’s existing Care Solutions portfolio.

Arron Chen, chairman and president of the Vland Group, expressed confidence in the joint venture’s ability to capitalize on their collective expertise and deliver impactful solutions for customers in China and beyond. 

With operations based at the Vland Biotech Park in Qingdao and utilizing Vland’s production facilities in Huimin, the joint venture is poised to emerge as a beacon of innovation, prioritizing customer proximity, quality, and efficiency.

Dr. Xu Wang, general manager of the joint venture, underscored Evonik Vland Biotech’s commitment to delivering value-driven products and solutions, backed by strong innovation capabilities and application technology know-how. 

The venture is primed to introduce new components for formulated products, thereby enriching Evonik’s gut health portfolio and paving the way for novel solutions in the field.

Notably, under the terms of the agreement with Vland, Evonik will also extend the distribution of the joint venture’s portfolio beyond the Greater China region. This strategic move underscores the joint venture’s role in complementing Evonik’s existing offerings and facilitating the introduction of new solutions for gut health on a global scale.

Gut health solutions constitute a cornerstone of Evonik’s Animal Nutrition business line, with probiotics such as Ecobiol, Fecinor, GutPlus, and GutCare playing pivotal roles in maintaining and restoring microbial balance in animal guts, thereby enhancing resilience.

For all the latest grains industry news from Africa, the Middle East, and the World, subscribe to our weekly NEWSLETTERS, follow us on LinkedIn, and subscribe to our YouTube channel.